Critical Review: ProKidney (NASDAQ:PROK) and Cartesian Therapeutics (NASDAQ:RNAC)

Cartesian Therapeutics (NASDAQ:RNAC) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Earnings and Valuation

This table compares Cartesian Therapeutics and ProKidney”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80 million	77.89	-$130.30 million	($5.94)	-1.21
ProKidney	$890,000.00	546.89	-$68.99 million	($0.55)	-2.93

ProKidney has lower revenue, but higher earnings than Cartesian Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cartesian Therapeutics and ProKidney, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1	1	5	0	2.57
ProKidney	1	0	1	1	2.67

Cartesian Therapeutics currently has a consensus price target of $32.60, suggesting a potential upside of 352.15%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 645.34%. Given ProKidney’s stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Cartesian Therapeutics.

Profitability

This table compares Cartesian Therapeutics and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
ProKidney	-10,288.39%	N/A	-27.39%

Institutional & Insider Ownership

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Summary

ProKidney beats Cartesian Therapeutics on 9 of the 14 factors compared between the two stocks.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.